| Anti-inflammatory effects of orally ingested lactoferrin and glycine in different zymosan-induced inflammation models: evidence for synergistic activity. | |
| | |
MedLine Citation:
|
PMID: 17996689 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
There is a growing awareness of the interaction of food constituents with the immune system. The present study aims to evaluate the anti-inflammatory effects of two of these nutritional components (glycine and bovine-lactoferrin (b-LF)) using two different mouse models. In a zymosan-induced ear-skin inflammation model both components decreased the inflammatory response locally (ear swelling and inflammatory cytokine concentration in the ears) and systemically (number of TNF-alpha producing spleen cells). Glycine effects (20, 50 or 100 mg/mouse/day) were concentration dependent. B-LF (0.1 or 1 mg/mouse/day) inhibited the inflammatory response although higher doses (5 and 25 mg/mouse/day) were not effective. A combination of b-LF 0.1 mg/mouse/day and glycine 20 or 50 mg/mouse/day counteracted the zymosan-induced ear swelling synergistically and enhanced the decrease in the number of TNF-alpha producing spleen cells of the individual components. In a zymosan-induced acute arthritis model glycine (50 mg/mouse/day) inhibited joint swelling, inflammatory cell infiltration and cartilage proteoglycan depletion. A b-LF dose of 5 mg/mouse/day reduced the zymosan-induced joint swelling without modulating inflammatory cell infiltration and cartilage proteoglycan depletion. The present study indicates that the anti-inflammatory effects of glycine are independent of the used models. B-LF displays a reversed concentration dependency and the activity is model dependent. A combination of glycine and lactoferrin demonstrated a synergistic anti-inflammatory effect on zymosan-induced skin inflammation and an enhanced decrease in the number of TNF-alpha producing spleen cells compared to the effect of the single components. Therefore, this nutritional concept might be a new option for the treatment of chronic inflammatory diseases. |
| | |
Authors:
|
Anita Hartog; Inge Leenders; Peter M van der Kraan; Johan Garssen |
Related Documents
:
|
7902659 - Polyamine and pentamidine metabolism in african trypanosomes. 20363689 - Impact of the aqueous extract of eclipta alba on maternal aggression in rats. 2177499 - Low-dose doxycycline therapy: effect on gingival and crevicular fluid collagenase activ... 20665369 - Assessment of the short-term safety and tolerability of a quantified 80 % ethanol extra... 21250929 - Meta-analysis of non-tumour doses for radiation-induced cancer on the basis of dose-rate. 21371459 - Evaluating the radioprotective effect of hesperidin in the liver of swiss albino mice. 11976829 - Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xe... 4005129 - A multiple dose pharmacokinetic and pharmacodynamic evaluation of conventional and 19/2... 11222879 - Developmental toxicity studies in rats and rabbits on 2,4-dichlorophenoxyacetic acid an... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2007-10-08 |
Journal Detail:
|
Title: International immunopharmacology Volume: 7 ISSN: 1567-5769 ISO Abbreviation: Int. Immunopharmacol. Publication Date: 2007 Dec |
Date Detail:
|
Created Date: 2007-11-12 Completed Date: 2008-01-24 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100965259 Medline TA: Int Immunopharmacol Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 1784-92 Citation Subset: IM |
Affiliation:
|
Numico Research, Wageningen, The Netherlands. anita.hartog@numico-research.nl |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Animals Anti-Inflammatory Agents / pharmacology* Disease Models, Animal Drug Synergism Glycine / administration & dosage, pharmacology* Inflammation / chemically induced, drug therapy* Lactoferrin / administration & dosage, pharmacology* Male Mice Mice, Inbred BALB C Proteoglycans / metabolism Tumor Necrosis Factor-alpha / biosynthesis Zymosan |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Inflammatory Agents; 0/Lactoferrin; 0/Proteoglycans; 0/Tumor Necrosis Factor-alpha; 56-40-6/Glycine; 9010-72-4/Zymosan |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Sulforaphane suppresses lipopolysaccharide-induced cyclooxygenase-2 (COX-2) expression through the m...
Next Document: Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular c...